Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs

A propensity-matched analysis from the Japanese Diagnosis Procedure Combination database

Mitsuhiro Nakamura, Hideo Yasunaga, Hiroaki Miyata, Takafumi Shimada, Hiromasa Horiguchi, Shinya Matsuda

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Neuroleptic malignant syndrome induced by atypical antipsychotics presents atypical clinical manifestations with fewer symptoms compared with neuroleptic malignant syndrome induced by typical antipsychotics. However, any differences in prognosis between these 2 types of drug-induced neuroleptic malignant syndrome remain unknown. We examined neuroleptic malignant syndrome-related mortality in patients treated with typical or atypical antipsychotics by using a national administrative claims database. Method: Data of patients with a diagnosis of neuroleptic malignant syndrome between July and December in each of the 5 years from 2004 to 2008 were extracted from the Japanese Diagnosis Procedure Combination database. Data included patient background, use of antipsychotics, and in-hospital mortality. Propensity score matching was performed to formulate a balanced 1:1 matched study and to compare in-hospital mortality between neuroleptic malignant syndrome patients taking typical antipsychotics and those taking atypical antipsychotics. Results: We identified 423 neuroleptic malignant syndrome patients treated with typical antipsychotics and 215 neuroleptic malignant syndrome patients treated with atypical antipsychotics. Matching based on propensity scores produced 210 patients in each drug group. In-hospital mortality was substantially lower in the atypical antipsychotic group compared with the typical antipsychotic group, but the difference was not significant (3.3% vs 7.6%; OR = 0.44; 95% CI, 0.17-1.11; P = .084). Conclusions: The results show that neuroleptic malignant syndrome remains a life threatening disease among patients receiving antipsychotics. A tendency for lower mortality in the atypical antipsychotic group may reflect differences in the pathophysiology. However, to clarify whether there is a difference in neuroleptic malignant syndrome-related mortality with the 2 types of antipsychotics, further studies with larger samples are needed.

Original languageEnglish
Pages (from-to)427-430
Number of pages4
JournalJournal of Clinical Psychiatry
Volume73
Issue number4
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Neuroleptic Malignant Syndrome
Antipsychotic Agents
Databases
Mortality
Hospital Mortality
Propensity Score
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs : A propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. / Nakamura, Mitsuhiro; Yasunaga, Hideo; Miyata, Hiroaki; Shimada, Takafumi; Horiguchi, Hiromasa; Matsuda, Shinya.

In: Journal of Clinical Psychiatry, Vol. 73, No. 4, 2012, p. 427-430.

Research output: Contribution to journalArticle

@article{15c59a2f2a414cbdb533e71b0280a3af,
title = "Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: A propensity-matched analysis from the Japanese Diagnosis Procedure Combination database",
abstract = "Objective: Neuroleptic malignant syndrome induced by atypical antipsychotics presents atypical clinical manifestations with fewer symptoms compared with neuroleptic malignant syndrome induced by typical antipsychotics. However, any differences in prognosis between these 2 types of drug-induced neuroleptic malignant syndrome remain unknown. We examined neuroleptic malignant syndrome-related mortality in patients treated with typical or atypical antipsychotics by using a national administrative claims database. Method: Data of patients with a diagnosis of neuroleptic malignant syndrome between July and December in each of the 5 years from 2004 to 2008 were extracted from the Japanese Diagnosis Procedure Combination database. Data included patient background, use of antipsychotics, and in-hospital mortality. Propensity score matching was performed to formulate a balanced 1:1 matched study and to compare in-hospital mortality between neuroleptic malignant syndrome patients taking typical antipsychotics and those taking atypical antipsychotics. Results: We identified 423 neuroleptic malignant syndrome patients treated with typical antipsychotics and 215 neuroleptic malignant syndrome patients treated with atypical antipsychotics. Matching based on propensity scores produced 210 patients in each drug group. In-hospital mortality was substantially lower in the atypical antipsychotic group compared with the typical antipsychotic group, but the difference was not significant (3.3{\%} vs 7.6{\%}; OR = 0.44; 95{\%} CI, 0.17-1.11; P = .084). Conclusions: The results show that neuroleptic malignant syndrome remains a life threatening disease among patients receiving antipsychotics. A tendency for lower mortality in the atypical antipsychotic group may reflect differences in the pathophysiology. However, to clarify whether there is a difference in neuroleptic malignant syndrome-related mortality with the 2 types of antipsychotics, further studies with larger samples are needed.",
author = "Mitsuhiro Nakamura and Hideo Yasunaga and Hiroaki Miyata and Takafumi Shimada and Hiromasa Horiguchi and Shinya Matsuda",
year = "2012",
doi = "10.4088/JCP.10m06791",
language = "English",
volume = "73",
pages = "427--430",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs

T2 - A propensity-matched analysis from the Japanese Diagnosis Procedure Combination database

AU - Nakamura, Mitsuhiro

AU - Yasunaga, Hideo

AU - Miyata, Hiroaki

AU - Shimada, Takafumi

AU - Horiguchi, Hiromasa

AU - Matsuda, Shinya

PY - 2012

Y1 - 2012

N2 - Objective: Neuroleptic malignant syndrome induced by atypical antipsychotics presents atypical clinical manifestations with fewer symptoms compared with neuroleptic malignant syndrome induced by typical antipsychotics. However, any differences in prognosis between these 2 types of drug-induced neuroleptic malignant syndrome remain unknown. We examined neuroleptic malignant syndrome-related mortality in patients treated with typical or atypical antipsychotics by using a national administrative claims database. Method: Data of patients with a diagnosis of neuroleptic malignant syndrome between July and December in each of the 5 years from 2004 to 2008 were extracted from the Japanese Diagnosis Procedure Combination database. Data included patient background, use of antipsychotics, and in-hospital mortality. Propensity score matching was performed to formulate a balanced 1:1 matched study and to compare in-hospital mortality between neuroleptic malignant syndrome patients taking typical antipsychotics and those taking atypical antipsychotics. Results: We identified 423 neuroleptic malignant syndrome patients treated with typical antipsychotics and 215 neuroleptic malignant syndrome patients treated with atypical antipsychotics. Matching based on propensity scores produced 210 patients in each drug group. In-hospital mortality was substantially lower in the atypical antipsychotic group compared with the typical antipsychotic group, but the difference was not significant (3.3% vs 7.6%; OR = 0.44; 95% CI, 0.17-1.11; P = .084). Conclusions: The results show that neuroleptic malignant syndrome remains a life threatening disease among patients receiving antipsychotics. A tendency for lower mortality in the atypical antipsychotic group may reflect differences in the pathophysiology. However, to clarify whether there is a difference in neuroleptic malignant syndrome-related mortality with the 2 types of antipsychotics, further studies with larger samples are needed.

AB - Objective: Neuroleptic malignant syndrome induced by atypical antipsychotics presents atypical clinical manifestations with fewer symptoms compared with neuroleptic malignant syndrome induced by typical antipsychotics. However, any differences in prognosis between these 2 types of drug-induced neuroleptic malignant syndrome remain unknown. We examined neuroleptic malignant syndrome-related mortality in patients treated with typical or atypical antipsychotics by using a national administrative claims database. Method: Data of patients with a diagnosis of neuroleptic malignant syndrome between July and December in each of the 5 years from 2004 to 2008 were extracted from the Japanese Diagnosis Procedure Combination database. Data included patient background, use of antipsychotics, and in-hospital mortality. Propensity score matching was performed to formulate a balanced 1:1 matched study and to compare in-hospital mortality between neuroleptic malignant syndrome patients taking typical antipsychotics and those taking atypical antipsychotics. Results: We identified 423 neuroleptic malignant syndrome patients treated with typical antipsychotics and 215 neuroleptic malignant syndrome patients treated with atypical antipsychotics. Matching based on propensity scores produced 210 patients in each drug group. In-hospital mortality was substantially lower in the atypical antipsychotic group compared with the typical antipsychotic group, but the difference was not significant (3.3% vs 7.6%; OR = 0.44; 95% CI, 0.17-1.11; P = .084). Conclusions: The results show that neuroleptic malignant syndrome remains a life threatening disease among patients receiving antipsychotics. A tendency for lower mortality in the atypical antipsychotic group may reflect differences in the pathophysiology. However, to clarify whether there is a difference in neuroleptic malignant syndrome-related mortality with the 2 types of antipsychotics, further studies with larger samples are needed.

UR - http://www.scopus.com/inward/record.url?scp=84860596511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860596511&partnerID=8YFLogxK

U2 - 10.4088/JCP.10m06791

DO - 10.4088/JCP.10m06791

M3 - Article

VL - 73

SP - 427

EP - 430

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -